MedTrace Logo

A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia

NCT00272207 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-08-25

No results posted yet for this study

Summary

The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

Nabilone

Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.

Sponsors & Collaborators

  • Valeant Canada Limited

    collaborator INDUSTRY

  • Winnipeg Regional Health Authority

    lead OTHER

Principal Investigators

  • Lena Galimova, MD · The Royal College of Physicians and Surgeons of Canada

  • Ryan Skrabek, MD · University of Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-02-28
Completion
2007-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272207 on ClinicalTrials.gov